Quimatryx S.L. logo

Quimatryx S.L.

Quimatryx develops new drugs against epigenetic targets. Quimatryx's main goal is the development of new selective inhibitors of HDAC6, a epigenetic target related with several diseases, such as cancer, central nervous system diseases or autoimmune disorders.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://quimatryx.com
Founded2015
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Paseo Mikeletegi 69, 3 planta 20009
San Sebastian
Spain
Email
Contact Number
+34 946 08 70 37

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/quimatryx” connections=”true” suffix=””]